Patents Assigned to Universite Claude Bernard Lyon
  • Publication number: 20250041221
    Abstract: The invention relates to a nanoparticle comprising at least one cationic lipid, at least one neutral lipid, and at least one pH sensitive lipid which differs from said cationic lipid, which can be used as a vector for the transport and release of nucleic acids within cells.
    Type: Application
    Filed: December 2, 2022
    Publication date: February 6, 2025
    Applicants: Universite Claude Bernard Lyon 1, Centre National de la Recherche Scientifique, Hospices Civils De Lyon, INSERM (Institut National de la Santé et de la Recherche Médicale), Universita Degli Studi Di Verona
    Inventors: Giovanna Lollo, Valentina Andretto, David Kryza, Eyad Al Mouazen, Mathieu Repellin, Stéphanie Briancon, Laurent Schaeffer, Jacquier Arnaud, Laurent Coudert
  • Patent number: 12202860
    Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.
    Type: Grant
    Filed: April 3, 2023
    Date of Patent: January 21, 2025
    Assignees: Institut National De La Sante Et De La Recherche Medicale (INSERM), Centre National De La Recherche Scientifique (CNRS), Ecole Normale Superieure De Lyon, Universite Claude Bernard Lyon 1
    Inventors: Théophile Ohlmann, Philippe Mangeot, Emiliano Ricci
  • Patent number: 12190746
    Abstract: A method for assisting a user in reading and in learning to read includes displaying a succession of graphemic entities on a screen. These are displayed with first values for several display parameters so as to enable a user to detect and identify them. The method continues with detecting when the user points to a particular graphemic entity with the first values of the display parameters. The screen then simultaneously displays those graphemic entities that are adjacent to the particular graphemic entity with the first values of the display parameters and the particular graphemic entity with second values for the display parameters. At least one of these second values differs from one of the first values for a given display parameter. This enables the user to identify the particular graphemic entity and causes acoustic rendering of a phonemic entity associated with the particular graphemic entity that the user pointed to.
    Type: Grant
    Filed: January 31, 2022
    Date of Patent: January 7, 2025
    Assignees: Universite Claude Bernard Lyon 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Angela Sirigu, Alice Gomez, Thomas Perret, Guillaume Lio, Jean-René Duhamel
  • Publication number: 20240409588
    Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.
    Type: Application
    Filed: June 13, 2024
    Publication date: December 12, 2024
    Applicants: Institut National De La Sante Et De La Recherche Medicale (INSERM), Centre National De La Recherche Scientifique (CNRS), Ecole Normale Superieure De Lyon, Universite Claude Bernard Lyon 1
    Inventors: Théophile OHLMANN, Philippe MANGEOT, Emiliano RICCI
  • Publication number: 20240343680
    Abstract: The present invention relates to a process for preparing aromatic acyl derivatives of formula (I) using methanesulfonic acid. The invention further relates to methods for preparing biological active ingredients. such as paracetamol.
    Type: Application
    Filed: October 27, 2022
    Publication date: October 17, 2024
    Applicants: Centre National de la Recherche Scientifique, Universite Claude Bernard Lyon 1, Institut National des Sciences Appliquees de Lyon
    Inventors: Estelle Metay, Marc Lemaire, Marie-Christine Duclos, Marc Daumas, Olivier Pardigon
  • Publication number: 20240294880
    Abstract: The invention provides a clonal cell line derived from a liver cancer cell line, preferably derived from a Huh7 hepatocarcinoma cell line, engineered to produce and secrete viral particles containing pregenomic RNA of the hepatitis B virus (HBV), predominantly over DNA of HBV, to calibrate quantitative HBV RNA assays.
    Type: Application
    Filed: February 29, 2024
    Publication date: September 5, 2024
    Applicants: Universite Claude Bernard Lyon 1, Centre National de la Recherche Scientifique, INSERM (Institut National de la Santé et de la Recherche Médicale), Hospices Civils De Lyon, Centre Leon Berard
    Inventors: Massimo Levrero, Fabien Zoulim, Alexia Paturel
  • Patent number: 12037453
    Abstract: The present invention relates to a polymer of the aromatic polyether type, containing a biosourced furan diol, to a method for producing said polymer, and to the use of said polymer for producing membranes.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: July 16, 2024
    Assignees: Roquette Freres, Universite Claude Bernard Lyon 1, Centre National de la Recherche Scientifique
    Inventors: Nicolas Jacquel, Sarah Degras, Régis Mercier, Thierry Delaunay
  • Publication number: 20240228546
    Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.
    Type: Application
    Filed: April 3, 2023
    Publication date: July 11, 2024
    Applicants: Institut National De La Sante Et De La Recherche Medicale (INSERM), Centre National De La Recherche Scientifique (CNRS), Ecole Normale Superieure De Lyon, Universite Claude Bernard Lyon 1
    Inventors: Théophile OHLMANN, Philippe MANGEOT, Emiliano RICCI
  • Publication number: 20240132547
    Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.
    Type: Application
    Filed: April 2, 2023
    Publication date: April 25, 2024
    Applicants: Institut National De La Sante Et De La Recherche Medicale (INSERM), Centre National De La Recherche Scientifique (CNRS), Ecole Normale Superieure De Lyon, Universite Claude Bernard Lyon 1
    Inventors: Théophile OHLMANN, Philippe MANGEOT, Emiliano RICCI
  • Publication number: 20240109940
    Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.
    Type: Application
    Filed: November 22, 2023
    Publication date: April 4, 2024
    Applicants: Institut National De La Sante Et De La Recherche Medicale (INSERM), Centre National De La Recherche Scientifique (CNRS), Ecole Normale Superieure De Lyon, Universite Claude Bernard Lyon 1
    Inventors: Théophile OHLMANN, Philippe MANGEOT, Emiliano RICCI
  • Patent number: 11845944
    Abstract: The disclosure relates to a promoter induced by fungal rust. More specifically, the promoter is induced by the pathogen Phakopsora pachyrhizi, i.e. the Asian Soybean Rust. The disclosure further provides for recombinant genes comprising the promoter and methods of producing a transgenic plant that involves introducing or providing the recombinant gene to plant cells to create transgenic plant cells, and regenerating transgenic plants from the transgenic cells.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: December 19, 2023
    Assignees: Centre National De La Recherche Scientifique, Institut National des Sciences Appliquees de Lyon, Universite Claude Bernard Lyon 1, BASF Agricultural Solutions Seed US LLC
    Inventors: Lisa Cabre, Sophie Ducerf, Stephane Peyrard, Catherine Sirven, Bernard Pelissier
  • Publication number: 20230278983
    Abstract: The present invention relates to indole derivatives of formula (I?) as CK2 inhibitor and pharmaceutical compositions comprising the same. The present invention further relates to the use of such compounds of formula (I) for use for preventing and/or treating a cancer.
    Type: Application
    Filed: July 6, 2021
    Publication date: September 7, 2023
    Applicants: Universite Claude Bernard Lyon 1, Institut National de la Sante et de la Recherche Madicale, Centre National de la Recherche Scientifique, Ecole Normale Superieure de Lyon, Commissariat à l'Energie Atomique et aux Energies AlternativesS, Centre Leon Berard
    Inventors: Alexandre Bancet, Claude Cochet, Odile Filhol-Cochet, Isabelle Krimm, Thierry Lomberget, Marc Le Borgne
  • Patent number: 11693003
    Abstract: The present invention relates to an in vitro method for evaluating the prognosis of an autoimmune or chronic inflammatory disease in an individual, comprising the following steps: a) determining (i) the level of an anti-IL-17 autoantibody and/or (ii) the level of an [IL-17/anti-IL-17 autoantibody] complex in a biological sample of the individual, and b) comparing the level of autoantibody and/or of complex determined in step a) with a reference value, the comparison being indicative of the prognosis of an autoimmune or chronic inflammatory disease in said individual.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: July 4, 2023
    Assignees: Hospices Civil de Lyon, Universite Claude Bernard Lyon 1, Eurobio Scientific
    Inventors: Pierre Miossec, Ndieme Thiam, Jean-Jacques Pin
  • Publication number: 20230045428
    Abstract: A system for the treatment of microorganisms includes: a textile web having optical fibers in warp and/or weft woven with binding threads in warp and/or weft, each of the optical fibers having invasive alterations along the fiber and allowing the emission of light propagating in the fiber at these alterations; a light source arranged opposite one or both free ends of the optical fibers. The textile web includes metallic warp and/or weft threads woven with the binding threads, the metallic threads being based on a metal having a negative effect on the growth of microorganisms. The light source generates a light beam having at least one wavelength in the visible or ultraviolet spectrum.
    Type: Application
    Filed: December 20, 2020
    Publication date: February 9, 2023
    Applicants: Brochier Technologies, Centre National de la Recherche Scientifique, Universite Claude Bernard Lyon 1, Institut National De La Sante Et De La Recherche Medicale, Ecole Normale Superieure De Lyon
    Inventors: Chantal GUILLARD, Christophe GILBERT, Cédric BROCHIER, Laure PERUCHON, Lina LAMAA, Davide LORITO
  • Patent number: 11529316
    Abstract: The invention relates to a novel use of ultrafine nanoparticles, of use as a diagnostic, therapeutic or theranostic agent, characterized by their mode of administration via the airways. The invention is also directed toward the applications which follow from this novel mode of administration, in particular for imaging the lungs, and the diagnosis or prognosis of pathological pulmonary conditions. In the therapeutic field, the applications envisioned are those of radiosensitizing or radioactive agents for radiotherapy (and optionally curietherapy), or for neutron therapy, or of agents for PDT (photodynamic therapy), in particular for the treatment of lung tumors.
    Type: Grant
    Filed: December 6, 2019
    Date of Patent: December 20, 2022
    Assignees: Universite Claude Bernard Lyon I, Nano-H, Centre National de la Recherche Scientifique—CNRS, Universite Grenoble Alpes, Universite de Bordeaux
    Inventors: Yannick Cremillieux, Andrea Bianchi, Sandrine Dufort, Jean-Luc Coll, Francois Lux, Olivier Tillement
  • Patent number: 11512003
    Abstract: The invention relates to a method for synthesizing ultrasmall silica nanoparticles, useful in particular for diagnostics and/or therapy. More specifically, a method for synthesizing silica nanoparticles, said method comprising the mixing of at least one silane which is negatively charged at physiological pH with at least one silane which is neutral at physiological pH, and/or at least one silane which is positively charged at physiological pH, wherein: —the molar ratio A of neutral silane(s) to negatively charged silane(s) is defined as follows: 0?A?6, —the molar ratio B of positively charged silane(s) to negatively charged silane(s) is defined as follows: 0?B?5, —the molar ratio C of neutral and positively charged silanes to negatively charged silane(s) is defined as follows: 0<C?8. The invention also relates to the obtained ultrasmall silica nanoparticles.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: November 29, 2022
    Assignees: NH THERAGUIX, Universite Claude Bernard Lyon 1, Centre National de La Recherche Gantifote—CNRS—
    Inventors: François Lux, Olivier Tillement, Fabien Rossetti, Vivek Thakare, Vu Long Tran
  • Publication number: 20220220027
    Abstract: The invention relates to a method for depositing metal particles on a textile support, which comprises: placing at least one textile sheet (1) made of side-emitting optical fibers (2) in contact with a solution containing at least one ionic precursor of a metal to be deposited, the textile sheet (1) being formed from optical fibers (2) woven in warp and/or weft with binding threads in warp and/or weft, each of the optical fibers (2) having invasive alterations (5) along the fiber and allowing the emission of light propagating in the fiber at these alterations (5), the textile sheet (1) being coated on all or part of the surfaces thereof with a layer of semiconductor particles (4) having photocatalytic properties, the textile sheet (1) and the solution being contained in a space of a reactor (9), the space being free of oxygen; illuminating the textile sheet (1) by at least one light source (7) connected to all or part of the free ends (6) of the optical fibers (2), the light source generating light radiati
    Type: Application
    Filed: May 5, 2020
    Publication date: July 14, 2022
    Applicants: Brochier Technologies, Centre National de la Recherche Scientifique, Universite Claude Bernard Lyon 1
    Inventors: Eric PUZENAT, Cédric BROCHIER, Davide LORITO, Lina LAMAA, Laure PERUCHON
  • Patent number: 11286557
    Abstract: A method of preparing a crystalline thin film having a formula MY2 includes (1) preparing an MYx amorphous film by atomic layer deposition on a surface of a substrate, and (2) annealing the amorphous MYx film at 350° C. or more to provide the crystalline MY2 film. The amorphous MYx film is formed from at least one metal M precursor and at least one element Y precursor, wherein x is 1.5 to 3.1, M is tungsten or molybdenum, and Y is sulfur or selenium. Step (1) includes a) introducing a first metal M precursor or element Y precursor into a deposition chamber, b) purging with inert gas, c) introducing a second metal M precursor when the first precursor is element Y, or element Y precursor when the first precursor is metal M, d) purging with inert gas, e) repeating steps a) to d), and f) obtaining the amorphous MYx film.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: March 29, 2022
    Assignees: Commissariat A L'Energie Atomique Et Aux Engergies Alternatives, Centre National De La Recherche Scientifique, Universite Claude Bernard Lyon 1, CPE Lyon Formation Continue et Recherche
    Inventors: Stéphane Cadot, Francois Martin, Elsje Quadrelli, Chloé Thieuleux
  • Patent number: 11180556
    Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4? T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: November 23, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D'AIX-MARSEILLE, Universite Claude Bernard—Lyon 1, Centre Leon Berard
    Inventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
  • Patent number: 11079391
    Abstract: The invention relates to an in vitro process for determining the functional IL-17 pro-inflammatory dependent level (IPDL) of a biological sample, comprising the following steps: a) measuring the level of an inflammatory marker produced by IL-17-sensitive cells incubated in the presence of a biological sample, b) measuring the level of said inflammatory marker produced by said cells incubated in the presence of a biological sample, in the presence of antibodies which neutralize the biological activity of IL-17, and c) determining the IPDL level, which is the difference between the level of said inflammatory marker measured in step a) and the level of said inflammatory marker measured in step b).
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: August 3, 2021
    Assignees: Hospices Civils de Lyon, Universite Claude Bernard Lyon 1
    Inventors: Pierre Miossec, Ndieme Thiam